CollPlant Biotechnologies Ltd. (CLGN)
- Previous Close
5.48 - Open
5.42 - Bid --
- Ask 5.89 x 1100
- Day's Range
5.42 - 5.89 - 52 Week Range
4.22 - 8.90 - Volume
5,872 - Avg. Volume
7,158 - Market Cap (intraday)
67.467M - Beta (5Y Monthly) 0.41
- PE Ratio (TTM)
-- - EPS (TTM)
-0.62 - Earnings Date May 22, 2024 - May 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.00
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; Tel Aviv University; Sheba Medical Center; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
www.collplant.comRecent News: CLGN
Performance Overview: CLGN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLGN
Valuation Measures
Market Cap
67.47M
Enterprise Value
43.95M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.12
Price/Book (mrq)
2.38
Enterprise Value/Revenue
4.01
Enterprise Value/EBITDA
-6.86
Financial Highlights
Profitability and Income Statement
Profit Margin
-64.05%
Return on Assets (ttm)
-13.06%
Return on Equity (ttm)
-23.16%
Revenue (ttm)
10.96M
Net Income Avi to Common (ttm)
-7.02M
Diluted EPS (ttm)
-0.62
Balance Sheet and Cash Flow
Total Cash (mrq)
26.67M
Total Debt/Equity (mrq)
11.15%
Levered Free Cash Flow (ttm)
-1.9M